Erlotinib (Tarceva)
Targeted Therapy · Approved since 2004
Description
Erlotinib is an oral tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). In colorectal cancer, erlotinib has been evaluated as a maintenance therapy following standard chemotherapy and bevacizumab treatment, particularly in patients with specific KRAS mutation status. The drug represents an EGFR-targeted approach for patients with metastatic colorectal cancer, though its efficacy in CRC is limited compared to other tumor types.
Mechanism of Action
Erlotinib works by selectively inhibiting the tyrosine kinase activity of EGFR, blocking downstream signaling pathways that promote tumor cell proliferation and survival. By binding to the ATP-binding site of EGFR, erlotinib prevents autophosphorylation and subsequent activation of pathways such as RAS/RAF/MEK and PI3K/AKT that drive cancer progression.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Tarceva |
| Category | Targeted Therapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2004 |
| Clinical Trials | 20 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.